<?xml version='1.0' encoding='utf-8'?>
<document id="26719074"><sentence text="A phase I clinical trial of the effect of belinostat on the pharmacokinetics and pharmacodynamics of warfarin."><entity charOffset="42-52" id="DDI-PubMed.26719074.s1.e0" text="belinostat" /></sentence><sentence text="Belinostat is a potent small molecule inhibitor that exerts its antitumor effect through inhibition of histone deacetylase"><entity charOffset="0-10" id="DDI-PubMed.26719074.s2.e0" text="Belinostat" /></sentence><sentence text=" The purpose of this study was to evaluate the pharmacokinetics and pharmacodynamics of warfarin (as a reference drug metabolized by CYP2C9) in the presence and absence of belinostat"><entity charOffset="172-182" id="DDI-PubMed.26719074.s3.e0" text="belinostat" /></sentence><sentence text="" /><sentence text="We conducted a phase I, single-center, open-label, drug-drug interaction study between belinostat and warfarin" /><sentence text=" In part I, patients were given warfarin 5 mg orally (day-14 and 3) and belinostat 1000 mg/m(2) (days 1 through 5)" /><sentence text=" Patients receiving benefit continued belinostat on days 1 through 5 every 21 days until disease progression, unacceptable toxicity, or per patient preference" /><sentence text="" /><sentence text="A total of 18 patients were treated" /><sentence text=" With belinostat, the least-squared means for maximum concentration (C max), area under the curve0-∞, and area under the curve0-t of R-warfarin were slightly increased"><entity charOffset="133-143" id="DDI-PubMed.26719074.s10.e0" text="R-warfarin" /></sentence><sentence text=" However, for the more potent S-warfarin isomer, the same parameters were primarily contained within the pre-specified equivalence limits of 0" /><sentence text="80 and 1" /><sentence text="25, indicating there was no statistically significant interaction between S-warfarin and belinostat"><entity charOffset="74-84" id="DDI-PubMed.26719074.s13.e0" text="S-warfarin" /><entity charOffset="89-99" id="DDI-PubMed.26719074.s13.e1" text="belinostat" /><pair ddi="false" e1="DDI-PubMed.26719074.s13.e0" e2="DDI-PubMed.26719074.s13.e0" /><pair ddi="false" e1="DDI-PubMed.26719074.s13.e0" e2="DDI-PubMed.26719074.s13.e1" /></sentence><sentence text=" The most common adverse events were nausea, vomiting, and fatigue" /><sentence text=" Three grade 3 adverse events (diarrhea 5" /><sentence text="6 %, nausea 5" /><sentence text="6 %, and vomiting 5" /><sentence text="6 %) were thought to be treatment related" /><sentence text=" Progression-free survival ranged from 0" /><sentence text="2 to 13" /><sentence text="8 months in all patients" /><sentence text="" /><sentence text="Belinostat did not significantly affect the pharmacokinetics and pharmacodynamics of warfarin, indicating no clinically relevant effect on the enzymatic activity of CYP2C9" /><sentence text="" /></document>